Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2013

View Archived Issues

Baxter and Coherus Biosciences to develop and commercialize biosimilar products

NIAID to expand funding for development of bicyclolide from Enanta

Kyowa Hakko Kirin and Ultragenyx collaborate on development of KRN-23

Arsanis raises funds for S. aureus program

Diaxonhit and Boehringer Ingelheim enter oncology target agreement

Treatment with CSL-112 leads to rapid removal of cholesterol from atherosclerotic plaques

Clinical comparison and evaluation of treatment dressings in skin graft donors

PV-10 induces systemic tumor-specific immune responses following intralesional injection

Treatment with herbal preparation STW-5-II prevents DSS-induced ulcerative colitis in vivo

Roche presents novel cathepsin S inhibitors

Researchers at Amgen design novel Na(v)1.7 channel blockers

Parkinson's UK provides grant to study PBT-434

SanBio completes enrollment in stem cell SB-623 trial

Addex Therapeutics reports additional preclinical data on dipraglurant

Amgen prepares new agents that inhibit the GCK-GCKR interaction

Navidea awarded additional grant for NAV-4694 beta-amyloid imaging agent

AstraZeneca begins phase III program for olaparib

BNO-1016 shows efficacy in patients with acute viral rhinosinusitis

Rockwell Medical reports findings from CRUISE-2 study of SFP

Syndax grants Eddingpharm Chinese rights to entinostat

Repligen receives milestone from Pfizer for spinal muscular atrophy program

Sanofi and Pozen sign U.S. commercialization agreement for PA-8140 and PA-32540

Neurodyn acquires Memogain from Galantos Pharma

Theravance reports topline results from phase IIb study of TD-4208 for COPD

Vedolizumab BLA for ulcerative colitis receives FDA priority review status

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...